FDA Delays Decision on Travere's Sparsentan for FSGS Treatment
The FDA has extended its review of Travere Therapeutics' Sparsentan for FSGS treatment, pushing the decision to April 2026. This has resulted in a 20% drop in Travere's stock price, adding uncertainty to the company's pipeline expansion.
Insights:
The U.S. Food and Drug Administration (FDA) has postponed its decision on Travere Therapeutics' application for expanded use of Sparsentan (Filspari) in treating focal segmental glomerulosclerosis (FSGS), a rare kidney disease. The regulatory body has extended its review timeline to April 13, 2026, after requesting additional data on the drug's clinical benefits. This delay has triggered a nearly 20% decline in Travere's stock price, reflecting investor concerns over the uncertainty surrounding this key pipeline expansion.
